Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.

[1]  R. Schinazi,et al.  Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy , 2000, Cancer Chemotherapy and Pharmacology.

[2]  E. Chu,et al.  Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Bertino,et al.  Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  O. Ashour,et al.  5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. , 1996, Biochemical pharmacology.

[5]  O. Ashour,et al.  Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside. , 1995, Cancer research.

[6]  F. Naguib,et al.  Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. , 1994, Cancer research.

[7]  E. Wang,et al.  5-Benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase. , 1993, Biochemical pharmacology.

[8]  C. Tzeng,et al.  Synthesis of a new class of uridine phosphorylase inhibitors , 1993 .

[9]  N. Kemeny,et al.  Uridine allows dose escalation of 5‐fluorouracil when given with N‐phosphonacetyl‐L‐Aspartate, methotrexate, and leucovorin , 1993, Cancer.

[10]  S. Soong,et al.  Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. , 1993, Biochemical pharmacology.

[11]  D. Baccanari,et al.  Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine. , 1993, Biochemical pharmacology.

[12]  G. Peters,et al.  Modulation of fluorouracil toxicity with uridine. , 1992, Seminars in oncology.

[13]  W. Gerok,et al.  Uridine catabolism by the isolated perfused rat liver. , 1992, Journal of hepatology.

[14]  P. Calabresi,et al.  Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine. , 1991, Biochemical pharmacology.

[15]  G. Peters,et al.  Clinical and pharmacologic study of orally administered uridine. , 1991, Journal of the National Cancer Institute.

[16]  A. Falcone,et al.  Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice , 1990 .

[17]  S. Soong,et al.  Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. , 1990, Biochemical pharmacology.

[18]  G. Peters,et al.  Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. , 1989, Journal of the National Cancer Institute.

[19]  R. Handschumacher,et al.  Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. , 1989, Pharmacology & therapeutics.

[20]  G. Peters,et al.  In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil. , 1988, British Journal of Cancer.

[21]  J. Pausch,et al.  Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys. , 1986, Cancer research.

[22]  H. M. Pinedo,et al.  Clinical and pharmacokinetic studies of prolonged administration of high dose uridine intended for rescue from 5 fluorouracil toxicity , 1986 .

[23]  H. D. Hochstein,et al.  Uridine‐induced hyperthermia in the rabbit , 1986, The Journal of pharmacy and pharmacology.

[24]  Handschumacher Re,et al.  Tissue-specific Enhancement of Uridine Utilization and 5-Fluorouracil Therapy in Mice by Benzylacyclouridine , 1985 .

[25]  J. Pausch,et al.  Uridine catabolism in Kupffer cells, endothelial cells, and hepatocytes. , 1985, European journal of biochemistry.

[26]  G. Peters,et al.  Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. , 1984, Cancer research.

[27]  A. Monks,et al.  Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. , 1983, Biochemical pharmacology.

[28]  P. Klubes,et al.  Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. , 1983, Cancer research.

[29]  S. Spiegelman,et al.  High-dose 5-fluorouracil with delayed uridine "rescue" in mice. , 1982, Cancer research.

[30]  A. Monks,et al.  Uridine regulation by the isolated rat liver: perfusion with an artificial oxygen carrier. , 1982, The American journal of physiology.

[31]  R. Handschumacher,et al.  Novel single-pass exchange of circulating uridine in rat liver. , 1981, Science.

[32]  R. Handschumacher,et al.  Salvage of circulating pyrimidine nucleosides in the rat. , 1981, Cancer research.

[33]  Dahnke Hg,et al.  In-vivo-Untersuchungen zur Metabolisierung der Pyrimidinnucleoside , 1975 .